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REVIEW ARTICLE
The synapse in traumatic brain injury
Aimun A. B. Jamjoom,1 Jonathan Rhodes,2 Peter J. D. Andrews2 and
Seth G. N. Grant1,3
Traumatic brain injury (TBI) is a leading cause of death and disability worldwide and is a risk factor for dementia later in life.
Research into the pathophysiology of TBI has focused on the impact of injury on the neuron. However, recent advances have
shown that TBI has a major impact on synapse structure and function through a combination of the immediate mechanical insult
and the ensuing secondary injury processes, leading to synapse loss. In this review, we highlight the role of the synapse in TBI
pathophysiology with a focus on the confluence of multiple secondary injury processes including excitotoxicity, inflammation and
oxidative stress. The primary insult triggers a cascade of events in each of these secondary processes and we discuss the complex
interplay that occurs at the synapse. We also examine how the synapse is impacted by traumatic axonal injury and the role it may
play in the spread of tau after TBI. We propose that astrocytes play a crucial role by mediating both synapse loss and recovery.
Finally, we highlight recent developments in the field including synapse molecular imaging, fluid biomarkers and therapeutics. In
particular, we discuss advances in our understanding of synapse diversity and suggest that the new technology of synaptome map-
ping may prove useful in identifying synapses that are vulnerable or resistant to TBI.
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Introduction
Traumatic brain injury (TBI) is a temporary or permanent im-
pairment of brain function due to an external mechanical force
to the head. It is a leading cause of death and disability world-
wide, with a rising global incidence due to increased use of
motor vehicles in low and middle income countries (Maas et al.,
2008). TBI leads to immediate functional impairment and there
is growing epidemiological evidence that TBI is major risk factor
for dementia later in life (Mortimer et al., 1985; Graves et al.,
1990; Fann et al., 2018; Gorgoraptis et al., 2019). There is also
evidence that TBI may be a risk factor for Parkinson’s disease
and stroke (Chen et al., 2011; Gardner et al., 2018). Although
most research into the mechanisms of TBI has focused on neur-
onal damage, recent advances have shown that synapses and
their intrinsic molecular pathways play a major role in a diverse
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range of brain diseases, raising the possibility that these may be
involved with TBI. Studies of the synapse proteome and gen-
ome sequencing of patients with developmental, psychiatric
and neurological disorders reveal that over 130 brain disor-
ders arise from mutations disrupting synapse proteins (Husi
et al., 2000; Grant et al., 2005; Pocklington et al., 2006;
Fernández et al., 2009, 2017; Feyder et al., 2010; Bayés et al.,
2011; Fromer et al., 2014; Purcell et al., 2014; Reig-Viader
et al., 2018; MacDonald et al., 2020). The remarkable burden
and diversity of synaptic diseases arising from these mutations
highlights the importance of maintaining appropriate levels of
synapse proteins for normal brain function. The postsynaptic
proteome of excitatory synapses comprises 41000 proteins
that are highly conserved between vertebrate species (Bayés
et al., 2011, 2012, 2017). These proteins are of many different
structural and functional classes, including neurotransmitter
receptors, ion channels, scaffolding, signalling and cytoskeletal
proteins (Husi et al., 2000; Peng et al., 2004; Collins et al.,
2006; Emes et al., 2008; Bayés et al., 2011, 2012, 2017;
Distler et al., 2014, Roy et al., 2018a, b).
Alongside evidence of the role of mutations in genes encoding syn-
apse proteins as the cause of a range of intrinsic brain disorders, syn-
apses also appear to be part of the early pathophysiology of
inflammatory and degenerative disorders such as multiple sclerosis
and Alzheimer’s disease (Wegner et al., 2006; Hong et al., 2016). In
Alzheimer’s disease, synapse loss correlates with cognitive decline and
is present in the prodromal stage of the disease (Scheff et al., 2006;
Sultana et al., 2010). This is important as there is growing evidence
that TBI, particularly repetitive injuries such as those experi-
enced by boxers and American football players, leads to a
neurodegenerative condition termed chronic traumatic en-
cephalopathy (CTE) (Stern et al., 2013). CTE pathology is
characterized by hyperphosphorylated tau protein as neuro-
fibrillary tangles, particularly within sulcal depths (McKee
et al., 2015). In Alzheimer’s disease, synapses appear to play
a role in disease progression through the trans-synaptic
spread of pathological tau (Spires-Jones and Hyman, 2014).
This raises the question of whether synapses play a role in
the progression of neurodegeneration following TBI.
In this review, we examine the role of the synapse in TBI
pathophysiology and draw attention to the confluence of
secondary injury processes that target synapses, the potential
mechanisms of synaptic loss and recovery after a traumatic
insult, and the role that neuroinflammatory cells play in this
process (Fig. 1). Coupled to this, we look at how the syn-
apse may contribute to disease through the trans-synaptic
spread of tau. Finally, we explore the direction in which the
burgeoning field of traumatic synaptopathy is heading.
Traumatic injury leads to
rapid changes in synapse
proteins and synapse loss
Early clues as to the effect of neuronal death on synapses
came from electron microscopy (EM) ultrastructural studies
that monitored synapse changes after denervation (Anderson
et al., 1986; Marrone et al., 2004). Neuron injury through
intraventricular injections of kainic acid or electroablation
demonstrated a significant reduction in synaptic density 3–4
days post lesion (Anderson et al., 1986; Marrone et al., 2004).
However, chemical lesions and electroablation may use differ-
ent pathways and mechanisms to TBI induced by mechanical
force. To overcome this, several preclinical studies have used
biochemical and microscopy methods to quantify synapse loss
in animal models of TBI (Table 1). In a controlled cortical im-
pact (CCI) model, Scheff et al. (2005) used EM to examine
synaptic (presynaptic terminal and postsynaptic density)
changes in the CA1 stratum radiatum of the hippocampal
formation and found the injury group had 44% synaptic
density compared with sham injury mice at 2 days post
injury. Gao et al. (2011) examined presynaptic punctum
number measured with synaptophysin and dendritic
density in the dentate gyrus using light microscopy and
immunohistochemistry and found the injury group had
69% synapse density compared with sham after a CCI.
The injury induced limited neuronal death but significant
reduction in dendritic density, highlighting that substan-
tial synapse loss can occur even without overt neuronal
Figure 1 Summary of pathological changes following trau-
matic brain injury. After TBI, synapse density is reduced for up to
7 days, followed by a recovery which plateaus around 30 days (Scheff
et al., 2005). Abnormal accumulation of APP peaks 1 day after TBI but
can persist for months to years after injury (Johnson et al., 2013). Tau
spreads through the brain after TBI and neurofibrillary tangles are a
hallmark of chronic traumatic encephalopathy (Edwards et al., 2020).
There is a rapid rise in extracellular glutamate after TBI, and levels
may remain abnormally elevated up to a week from the injury (Vespa
et al., 1998; Hong et al., 2001). Microglia show bimodal peaks after TBI
at 7 days and then 30 days (Simon et al., 2017). Markers of oxidative
stress appear rapidly after injury and may persist up to 6 months after
TBI (Licastro et al., 2016).
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death. Dendritic spine loss without neuronal death has
been found in other TBI preclinical studies (Posmantur
et al., 1996; Huh et al., 2003). Together, these studies
support the view that TBI induces synapse loss within the
first 48 h post injury within the hippocampus ipsilateral
to the injury.
A limitation of many of these studies is that they only
examined single subregions within the brain and therefore
provided limited conclusions about the potential differen-
tial effects of TBI on other brain regions. Biochemical
approaches provide a more global picture of changes in
synaptic protein levels; however, they are limited by the
loss of spatial information as part of the tissue homogen-
ization process. Using western blotting in a CCI model,
Wakade et al. (2010) found that 7 days after injury there
was a 47% reduction in postsynaptic density protein 95
(PSD95, a postsynaptic protein) expression in the hippo-
campus. A similar study assessed several synaptic proteins
(PSD95, synapsin 1, SAP97 and GAP43) in the hippo-
campus at multiple time points post CCI using western
blotting (Ansari et al., 2008b) and found significant
reductions in PSD95 and synapsin 1 (a presynaptic
protein) at 48 h, which persisted until 96 h post injury.
Yu et al. (2015) corroborated these findings using a
systems biology approach involving gene expression data
from four different TBI animal models and found a sup-
pressed network of synaptic proteins centred around
PSD95. Although limited, there have been observations of
synaptopathy in human cases of TBI. Castejòn et al.
(1995) undertook a small case series examining human
Table 1 Summary of animal studies examining synaptic changes after TBI
Injury model Species Time after
injury
Assay Marker Synapse pathology Reference
Controlled cortical impact
Injury severity
Diameter,
mm
Depth,
mm
Velocity,
m/s
3 1 3.0 Mouse 1–7 days IHC Synaptophysin Molecular layer of the hippocampal
dentate gyrus; 30% loss in pre-
synaptic puncta density at 3 days
Gao et al., 2011
3 1 4.5 Mouse 1–7 days WB PSD95 Hippocampus; postsynaptic PSD95
reduced at 7 days
Wakade et al.,
2010
3 1 6.0 Mouse 1–7 days IHC VGlut1 Hippocampus CA1 stratum radia-
tum; 27% loss in presynaptic
puncta density 3 days
Nikolakopoulou
et al., 2016
5 2 3.5 Rat 2–60 EM N/A Hippocampus CA1 stratum radia-
tum; 66% synapses lost at 2 days;
14% synapses lost at 30 days
Scheff et al.,
2005
5 2 3.5 Rat 3 h–4 days WB Synapsin; PSD95;
SAP97; GAP43
Neocortex; presynaptic synapsin
reduced from 1 to 4 days; postsy-
naptic PSD95 reduced from 1 to 4
days; SAP97 reduced at 4 days;
GAP43 no change
Ansari et al.,
2008a
5 2 3.5 Rat 1 h–4 days WB Synapsin; PSD95
SAP97; GAP43
Hippocampus; postsynaptic PSD95
reduced from 2 days; presynaptic
synapsin reduced from 2 days;
SAP97 reduced at 4 days; GAP43
no change
Ansari et al.,
2008b
Lateral fluid percussion injury
Injury severity
Low (1.9 ± 0.2 atm)
Moderate (3.3 ± 0.3 atm)
High (6.0 ± 0.5 atm)
Rat 2–30 days WB
IHC
Synaptophysin Neocortex; increased presynaptic
synaptophysin IHC with increasing
severity of injury; no difference in
synaptophysin WB between sham
and moderate injury from 2 to 30
days
Shojo and
Kibayashi,
2006
Rotatory head model
Undefined Rat 1–30 days EM N/A Sensorimotor cortex; 14% synapses
lost at 1 day; 36% synapses lost at
7 days; 18% synapses lost at 30
days
Semchenko
et al., 2006
Blast injury
15.8 psi 5.9 ms 1.4 Mach Mouse 1–30 days WB PSD95 Cerebellum; PSD95 reduced at 30
days
Meabon et al.,
2016
IHC = immunohistochemistry; N/A = not available/applicable; WB = western blot.
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cortical tissue samples after TBI. Using EM, the authors
found evidence of swollen and shrunken presynaptic ter-
minals and separation from the postsynaptic density. The
authors also described dendritic swelling and evidence of
synaptic phagocytosis by astroglial cells. These studies
provide useful insights into the impact of TBI on the syn-
apse. However, any conclusions are limited by the prepon-
derance of murine TBI models and the use of post-mortem
tissue, which only provides a snapshot of the state of the
synapse after injury. Coupled to this, the imaging and
biochemical approaches used provide only limited spatial
information.
Taking these limitations into account, these data point to-
wards a vulnerability of synapses to traumatic insult, with
evidence of synapse loss from 2 to 7 days post injury across
differing TBI preclinical models and quantification techni-
ques (Fig. 1). Together, these studies converge on the view
that TBI results in the loss of synapses as well as a reduction
in the expression of synapse proteins and their mRNAs.
Relationship between
traumatic axonal injury and
synaptopathy
It is important to consider the mechanical damage caused to
the axon and how this impacts on synapse number and
function. TBI induces dynamic deformation of long white
matter tracts resulting in disruption of the axons (Johnson
et al., 2013). This can either lead to primary axotomy or
partial damage leading to progressive axonal dysfunction
and delayed axonal degeneration (Hill et al., 2016).
Historically, traumatic axonal injury was determined using
histological approaches such as haematoxylin and eosin or
silver staining (Smith et al., 2013a). However, the introduc-
tion of immunohistochemistry allowed for more specific
labelling of proteins transported in axons. For example,
amyloid precursor protein (APP) moves along the axon by
anterograde transport (Smith et al., 2013a). Mechanical per-
turbation of the axon leads to pooling of APP, and accumu-
lation of this transported material leads to either varicosities
along the length of the axon or, in the event of complete dis-
connection, an axonal bulb (Johnson et al., 2013). Using
APP as a marker, axonal injury appears to peak at 24 h and
subsequently declines, although evidence of pathology can
persist months after TBI (Fig. 1) (Johnson et al., 2013).
Canty and colleagues used two-photon microscopy and laser
microsurgery to examine the effect of axotomy on presynap-
tic bouton dynamics in vivo at a single-axon level (Canty
et al., 2013b). The authors observed disappearance of the
axon distal to the injury but also, very importantly, rapid
reductions in bouton density along the injured proximal
axon within 6 h. They also found that the degree of synaptic
loss was dependent on the cell type and the prelesion axon
structural dynamics. This suggests that damage to the axon
interferes with the synapses located proximal and distal to
the lesion site.
Axons within a single specimen can be found in differing
stages of degeneration and disconnection, highlighting that
TBI-induced damage is an evolving pathology (Johnson
et al., 2013). The pathophysiology of this process is believed
to be related to dysregulation of Na+ channels, leading to a
Ca2 + influx. The accumulation in Ca2 + , which is due to
both influx and the release from intracellular stores (Wolf
et al., 2001; Staal et al., 2010), activates proteases, such as
calpain, which proteolyse voltage-gated Na+ channels (von
Reyn et al., 2009). This process leads to loss of microtubules
and energy failure secondary to mitochondrial damage and
ultimately impairs axonal transport (Wolf et al., 2001,
Smith et al., 2013a). In severe cases, axotomy and Wallerian
degeneration occur within the distal axon.
Insight into the relationship of axonal damage and syn-
apse loss has been aided by the Wallerian degeneration slow
(Wlds) mutation, which is known to confer protection to
axonal degeneration (Mack et al., 2001) in a variety of de-
generation-inducing models (Wang et al., 2001; Gillingwater
et al., 2004; Sajadi et al., 2004). In the context of trauma, a
study using a cortical lesion model found evidence of degen-
erating presynaptic terminals in the striatum at Day 2 post
lesion in wild-type mice, which peaked at Day 3 and had
resolved by Day 10, but was delayed and less pronounced in
Wlds mice (Gillingwater et al., 2006). The Wlds gene enco-
des the nicotinamide adenine dinucleotide (NAD+) biosyn-
thetic enzyme nicotinamide mononucleotide
adenylyltransferase 1 (NMNAT1) fused to an 18-amino acid
sequence from the N-terminus of Ube4b (ubiquitylation en-
zyme) (Mack et al., 2001). The Wlds protein localizes to the
neuron’s nucleus, where it potentially regulates both axonal
and dendritic proteins (Mack et al., 2001). Proteomic ana-
lysis demonstrated modified expression of 16 synapse pro-
teins, suggesting that the Wlds neuroprotective phenotype
may be related to altered mitochondrial activity and changes
to both the ubiquitin-proteasome and NAD-associated path-
ways (Wishart et al., 2012). Thus, the protective effect of the
Wlds gene on synapse loss may involve a postsynaptic
mechanism.
A second major molecule of interest in axonal degener-
ation is sterile alpha and TIR motif-containing protein 1
(SARM1) (Osterloh et al., 2012). SARM1 has been impli-
cated in NAD+ metabolism, with evidence of suppressed
NAD+ loss and axonal degeneration when SARM1 is
knocked down (Gerdts et al., 2015). A study examining the
impact of SARM1 in TBI found evidence of attenuated trau-
matic injury and improved functional outcome in SARM1
knockout mice after CCI (Henninger et al., 2016). Genetic
ablation of SARM1 prevented loss of corticospinal axons
after an acceleration injury (Ziogas and Koliatsos, 2018).
Collectively, these data suggest a mechanistic role of both
SARM1 and NMNAT1 in mediating traumatic axonal de-
generation. Less is known about the impact of these mole-
cules on traumatic synaptopathy. Axonal protection appears
to minimise synaptic loss; however, the exact relationship
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between SARM1 and NMNAT1 has yet to be fully eluci-
dated in the context of TBI.
The synapse and secondary
injury processes
Synaptopathy in TBI is likely to be a complex, dynamic and
multifaceted process. The mechanical injury (primary insult)
causes instantaneous tissue damage, which is followed by
multiple secondary injury processes (Prins et al., 2013). These
begin within seconds to minutes after the primary injury and
can last for months to years. In the following section, we dis-
cuss excitotoxicity, oxidative stress and inflammation and ex-
plore the role of the synapse in these processes.
Glutamate excitotoxicity
Glutamate is the major neurotransmitter in the brain and is
released from all excitatory synapses. Traumatic injury leads
to an increase in extracellular glutamate levels, which
appears within 24 h after injury and has been found to be
abnormally elevated for up to a week in TBI patient CSF
(Vespa et al., 1998; Hong et al., 2001) (Fig. 1). Glutamate
acts upon two main neurotransmitter receptors on the post-
synaptic terminal: NMDA receptors and AMPA receptors.
These are ligand-gated ionotropic receptors, which play an
important role in synaptic transmission and plasticity
(Voglis and Tavernarakis, 2006; Paoletti et al., 2013).
AMPA receptors are principally involved in gating Na+ in-
flux that depolarizes the postsynaptic neuron, whereas
NMDA receptors gate the influx of Ca2 + crucial for signal
transduction (Fig. 2). In TBI, elevated glutamate levels lead
to abnormal intracellular Ca2 + levels and contribute to neur-
onal death (Nilsson et al., 1996).
AMPA receptors consist of four subunits (GLuR1–4) and
several studies have shown that TBI-related glutamate
increases can lead to changes in AMPA receptors that per-
petuate glutamate toxicity by exacerbating Ca2 + overload
(Spaethling et al., 2008; Bell et al., 2009). The release of
intracellular Ca2 + leads to the expression of AMPA recep-
tors that lack the GluR2 subunit, making the receptor highly
permeable to Ca2 + (Spaethling et al., 2008). This shift in
AMPA receptor subtype is an important factor in exacerbat-
ing excitotoxic neuronal death within an hour after injury.
The NMDA receptor binds to PSD95, which in turn inter-
acts with PKCa (Husi et al., 2000; Frank et al., 2016)—the
protein kinase that phosphorylates the GluR2 subunit of the
AMPA receptor—which induces GluR2-deficient AMPA
receptors and exacerbates TBI excitotoxicity (Fig. 2).
Oxidative stress
Oxidative stress arises from an overproduction of reactive
oxygen species or dysfunction of the antioxidant system
(Chen et al., 2012). There is a range of reactive oxygen spe-
cies, including hydroxyl, superoxide, nitric oxide and lipid
peroxyl. The abundance of reactive oxygen species leads to
cellular dysfunction through lipid peroxidation and DNA
damage and has been implicated in a range of neurodegener-
ative diseases (Gandhi and Abramov, 2012). Evidence of
oxidative stress following TBI has been found in both pre-
clinical and human studies (Hall et al., 1993; Cernak et al.,
2000; Tyurin et al., 2000; Toczyłowska et al., 2006; Wang
et al., 2016a) and has been found to persist up to 6 months
after TBI (Licastro et al., 2016) (Fig. 1). The synapse plays
an important role in the convergence of glutamate toxicity
and oxidative stress. Activation of the NMDA receptor and
the influx of Ca2 + leads to the generation of reactive oxygen
and nitrogen species (Szydlowska and Tymianski, 2010). In
addition to the central role of PSD95 in coupling PKCa to
NMDA receptors, it also interacts with neuronal nitric oxide
synthase (nNOS), which generates nitric oxide (Brenman
et al., 1996) (Fig. 2), a free radical that plays a role in both
inflammation and oxidative stress (Kobayashi, 2010;
Cornelius et al., 2013). Nitric oxide and peroxide form the
reactive nitrogen species peroxynitrite, which is highly react-
ive and can nitrate tyrosine residues of proteins (Gandhi and
Abramov, 2012). The physical coupling of nNOS to the
NMDA receptor is key in oxidative damage, and disrupting
PSD95 reduces cell death in an in vitro model of TBI
(Arundine et al., 2004; Bach et al., 2019). Interestingly, a
study using a systems biology approach to analyse gene ex-
pression data from multiple TBI animal models highlighted
nNOS and PSD95 as potential protein markers of TBI (Yu
et al., 2015).
Figure 2 TBI secondary injury and the postsynaptic dens-
ity. There is a surge of glutamate following TBI (a) (Vespa et al.,
1998; Hong et al., 2001), which leads to influx of Ca2 + into the cell
at the NMDA and AMPA receptors (b) (Nilsson et al., 1996).
PSD95, which is bound to PKCa, promotes GluR2-deficient AMPA
receptors and exacerbates TBI excitotoxicity (c) (Spaethling et al.,
2008). The release of TNFa also acts upon the AMPA receptors
and reduces expression of GluR2, which worsens excitotoxicity (d)
(Beattie et al., 2002; Stellwagen et al., 2005). Triggered by CR3,
microglia lead to long-term depression by activation of NADPH
oxidase and GluR2-mediated AMPA receptor internalization (e)
(Zhang et al., 2014). PSD95 is bound to neuronal nitric oxide syn-
thase which plays a role in promoting oxidative stress (f) (Brenman
et al., 1996).
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Two studies have also explored the relationship between
oxidative stress and synaptic proteins in the cortex and
hippocampus in a preclinical model of TBI (Ansari et al.,
2008a, b). A temporal analysis of post-mortem tissue
showed evidence of oxidative stress with increased protein
carbonyl, 3-nitrotyrosine and acrolein. These markers of oxi-
dative stress preceded a reduction of PSD95 expression at
24 and 48 h post injury within the cortex and hippocampus,
respectively. Although these findings do not support a
causative relationship, this association suggests that the
overwhelming of the antioxidant system after TBI may play
a role in post-injury synaptopathy and warrants closer
investigation.
There have been attempts to target oxidative stress as a
therapeutic avenue in TBI. Magnesium has been investigated
as it has a role as both a non-competitive NMDA receptor
antagonist and has been shown to protect neurons against
oxidative stress (Ruppersberg et al., 1994; Regan et al.,
2002). A study of 31 TBI patients demonstrated a reduction
in serum magnesium levels that negatively correlated with
markers of oxidative stress (Cernak et al., 2000). Coupled to
this, preclinical studies showed that magnesium supplemen-
tation could ameliorate neuronal injury after TBI (Bareyre
et al., 2000; Saatman et al., 2001). This led to a randomized
clinical trial examining the efficacy of a magnesium sulphate
infusion following TBI (Temkin et al., 2007). The trial found
that magnesium had no positive impact on clinical outcome
following TBI and that the treatment group had an increase
in medical complications. These findings have ruled out
magnesium for the treatment of TBI.
Inflammation
Inflammation is a well-described secondary injury process
following TBI (Simon et al., 2017). There is growing evi-
dence that the inflammatory process acts upon the synapse
to mediate neuronal damage. Tumour necrosis factor alpha
(TNFa) is a proinflammatory cytokine that infiltrates the in-
jury site and reduces expression of AMPA GluR2 subunits
(Beattie et al., 2002; Stellwagen et al., 2005) (Fig. 2). As
described above, these changes in AMPA structure can lead
to Ca2 + overload and increase cell death. More recently,
Zhang et al. (2014) found in an in vitro model of ischaemia
and inflammation that activation of microglial complement
receptor 3 (CR3) triggers long-term depression of synaptic
transmission by activation of NADPH oxidase and internal-
ization of GluR2-containing AMPA receptors (Zhang et al.,
2014) (Fig. 2). Long-term depression is thought to underlie
cognitive functions (Bear and Abraham, 1996) and thus in-
flammatory processes may contribute to post-traumatic cog-
nitive impairments.
A particularly important question is the role of glial cells
in synaptopathy. Several studies have made observations
linking microglia to synapse removal in different disease
models. In TBI, microglia appear to undergo a bimodal in-
crease, with an early peak at 7 days followed by a later peak
around 28 days (Simon et al., 2017) (Fig. 1). Wake et al.
(2009) used two-photon microscopy and found that transi-
ent cerebral ischaemia led to more prolonged contact be-
tween microglia and the presynaptic terminal, following
which, several boutons were noted to have disappeared.
Similarly, Hong et al. (2016) looked at a murine model of
Alzheimer’s disease and observed early synapse (co-localized
pre- and postsynaptic puncta) loss that preceded plaque for-
mation. The authors described microglia engulfment of syn-
aptic elements, which was not observed in mice with CR3
knockout (a high-affinity receptor expressed on macro-
phages) and a rescue of synaptic loss. They concluded that
the complement cascade and microglia mediate early synap-
tic loss in Alzheimer’s disease. An in vitro study that aimed
to model inflammation and ischaemia (two important path-
ologies in TBI) found evidence that the two processes act
synergistically through microglial CR3 to induce long-term
depression of synaptic transmission (Zhang et al., 2014).
These data point towards a potential role of microglia in
synaptic pruning; however, there is a lack of conclusive
mechanistic evidence, particularly in the context of TBI. It
will therefore be of importance to address the role of micro-
glia in the early and late phases of TBI.
Oligodendrocytes are the myelinating cells of the CNS,
and are derived from the oligodendrocyte progenitor cell
(OPC) lineage (Bradl and Lassmann, 2010). In a model of
experimental demyelination, OPCs were observed to develop
transient synaptic connections (evoked excitatory postsynap-
tic currents) with callosal axons prior to differentiation into
oligodendrocytes during the remyelination phase (Etxeberria
et al., 2010). Myelin and axonal injury are well-described
pathological processes in TBI (Armstrong et al., 2016). A
similar pattern of OPC and oligodendrocyte proliferation
has been observed in the corpus callosum following an ex-
perimental model of TBI (Sullivan et al., 2013). This may
suggest that synapse-mediated axon-OPC interactions play a
role in post-traumatic remyelination.
The role of the astrocyte has also been explored in the
context of TBI. Furman et al. (2016) examined the effect of
blocking the astrocytic calcineurin/nuclear factor of activated
T cells (NFAT) signalling pathway on hippocampal synaptic
function and protein levels. Using an adeno-associated virus
delivery system to deliver VIVIT (an NFAT inhibitory pep-
tide), the authors found a prevention of injury-induced syn-
aptic strength loss in CA1 and an associated reduction in
postsynaptic density protein loss (PSD95 and GluR1)
(Fig. 3). Interestingly, these events occurred without a signifi-
cant change in the number of astroglia between the treated
and control rodents, indicating that the protective effects of
VIVIT on the synapse do not require an associated reduction
in glial activation. Astrocytes have also been implicated in
propagating synaptic damage by the release of D-serine.
Perez et al. (2017) found a shift from neuronal to astrocytic
D-serine release (which activates NMDA receptors) after
CCI. Using electrophysiology to measure synaptic transmis-
sion, the authors found that astrocyte-specific elimination of
D-serine rescued synaptic plasticity (Fig. 3). Similarly,
Nikolakopoulou et al. (2016) found evidence of the
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involvement of astrocytic ephrin B1 in synaptic remodelling
after a moderate CCI in mice. After injury, an upregulation
of ephrin B1 was observed that coincided with a decrease in
the presynaptic protein VGlut1 (Fig. 3). Ablation of ephrin
B1 accelerated the recovery of VGlut1 puncta. The authors
linked ephrin B1 to STAT3 phosphorylation, which they
implicated in synaptic remodelling. These studies suggest
that astrocytes may play a role in synapse damage after TBI
through a number of mechanisms.
To establish closer links between the inflammation re-
sponse and the routes to synapse damage, it will be import-
ant to understand the complex intercellular interactions,
their spatial relationships and the molecular mechanisms
involved, which is being advanced by spatial transcriptomics
and in situ sequencing methods (Chen et al., 2020). These
approaches combined with cell-type manipulation of mo-
lecular function (using genetic and optogenetic tools) could
be used to dissect the temporal sequence of events at the mo-
lecular and cellular levels.
The synapse, tau and
progression of
neurodegeneration after TBI
It has long been known that TBI can lead to neurodegenera-
tion later in life. In 1928, the pathologist Harrison Martland
published a seminal paper describing ‘punch drunk syn-
drome’, a constellation of chronic motor and neuropsychi-
atric symptoms in former boxers (Martland, 1928). The
term dementia pugilistica was ascribed to the progressive
neuropsychiatric condition that emerged after repetitive mild
TBI, and a number of case series indicated a neuropatho-
logical basis to the syndrome (Corsellis, 1989; Roberts et al.,
1990). However, interest in the condition was limited up
until the past decade when similar findings were made in
non-boxing contact sports such as in American football and
in military personnel (McKee et al., 2009; Omalu et al.,
2011). The term CTE was introduced to describe the clinico-
pathological condition emerging from a wide range of phys-
ical exposures. One of the most consistent neuropathological
findings in CTE is the presence of neurofibrillary tangles,
which has led to it being described as a ‘tauopathy’ (McKee
et al., 2009). By contrast, the presence of amyloid-b (an im-
portant feature in Alzheimer’s disease) is a less consistent
feature in CTE (Smith et al., 2013b).
The synapse appears to play an important role in
Alzheimer’s disease progression through its interaction with
tau. In Alzheimer’s disease, tau systematically spreads
through the brain, starting within the hippocampal forma-
tion then limbic and association cortices and finally to other
parts of the brain (Braak and Braak, 1991). Trans-synaptic
transmission has been suggested as the mechanism underpin-
ning the circuit-driven spread of pathological tau in
Alzheimer’s disease (De Calignon et al., 2012; Liu et al.,
2012). In CTE, the anatomical progression of tau differs
from that of Alzheimer’s disease, starting as scattered foci in
the frontal lobe then progressing to the depth of sulci before
spreading across the brain (McKee et al., 2015).
Interestingly, in CTE the medial temporal lobe is affected
Figure 3 Role of astrocytes in post-traumatic synapse loss and repair. The upregulation of astrocytic ephrin B1 and STAT3 phosphoryl-
ation following TBI have been found to coincide with a decrease in VGlut1 (a) (Nikolakopoulou et al., 2016). The tonic release of astrocytic D-ser-
ine has been associated with synapse damage after TBI (b) (Perez et al., 2017). Astrocytic calcineurin/NFAT signalling pathway induces synaptic
strength loss in CA1 and a reduction in synaptic protein loss (PSD95 and GluR1) (c) (Furman et al., 2016). MMP3 has been implicated in maladap-
tive synaptic recovery after TBI (e) (Falo et al., 2006). Hevin has been shown to promote post-traumatic synaptogenesis which was amplified by
the blockade of the calcineurin/NFAT pathway (d) (Furman et al., 2016). Thrombospondin 1 (which is regulated by STAT3) has been found to pro-
mote synapse recovery after motor neuron injury (f) (Tyzack et al., 2014).
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later in the disease, whereas in Alzheimer’s disease it is
where the disease process starts. An experiment using P301S
transgenic mice (which express mutant human tau) found
accelerated spreading of phosphorylated tau after a single
TBI, which the authors postulated to be synaptic-driven
spread based on the progression pattern (Edwards et al.,
2020). Although this study could not make a conclusion on
the mechanism underpinning the spread of tau, it does high-
light this as an interesting area of study and the potential
role that the synapse may play in the progression of neuro-
degeneration following TBI.
The potential for synapse
recovery after TBI
Several studies have identified the potential for synapse re-
covery after TBI, principally through the process of synapto-
genesis (Fig. 1). Two studies examined reactive
synaptogenesis using EM in preclinical models of TBI
(Table 1). Scheff et al. (2005) found a partial recovery of
hippocampal CA1 synapse (presynaptic terminal and postsy-
naptic density) density at 10 days post injury, which contin-
ued to Day 30 and reached up to 86% of control levels.
Semchenko et al. (2006) used a rotatory head injury model
in rats and found that an initial decrease in sensorimotor
cortical synaptic (presynaptic terminal and postsynaptic
density) density was followed by an increase from Day 7 to
Day 30 post injury compared with control. Interestingly, a
study by Canty using laser axotomy and two-photon micros-
copy observed regeneration in a subset of axons that then
went on to form presynaptic boutons with prelesional den-
sities (Canty et al., 2013a). These observations point to-
wards a degree of limited or maladaptive synaptic
reorganization post injury.
The mechanisms underlying post-injury synaptogenesis
have been investigated. Astrocytic matrix metalloproteinase
3 (MMP3), an enzyme involved with the breakdown of the
extracellular matrix, has been implicated in maladaptive syn-
aptic recovery after TBI (Huntley, 2012). A study comparing
deafferentation alone with deafferentation and fluid percus-
sion injury found persistently elevated MMP3 in both mod-
els, for which there was significant co-localization to
astrocytes in the combined injury group (Falo et al., 2006).
Pharmacological inhibition of MMP3 led to increases in the
thickening of the excitatory synapse postsynaptic density,
measured using EM, and an improvement in spatial learning
(Fig. 3). Similarly, Tyzack et al. (2014) examined the role of
astrocytic STAT3 in synaptic (presynaptic terminal and post-
synaptic density) remodelling in a facial murine nerve axot-
omy model. The authors implicated astrocytic STAT3-
regulated release of thrombospondin-1 (THBS1) in post-injury
synaptic remodelling (Fig. 3). The study found that knock-
out of the Thbs1 gene led to impaired synaptic recovery,
which mirrored findings in a model of cerebral ischaemia
that showed deficits in synaptic density and functional
recovery with knockout of Thbs1/Thbs2 (Liauw et al.,
2008). In TBI, there is evidence of thrombospondin upregu-
lation in both in vitro and in vivo models (Tran et al.,
2012; Wang et al., 2016b). Plasma levels of THBS1 have
also been found to be elevated in patients with TBI and
may act as a prognostic biomarker (Wang et al., 2016b).
Astrocytes may also play a role in post-injury circuit re-
organization by the secretion of Hevin, a synaptogenic pro-
tein (Singh et al., 2016). Furman et al. (2016) found an
increase in Hevin levels in injury mice compared with
sham, which was further amplified by the blockade of the
calcineurin/NFAT signalling pathway (Furman et al., 2016)
(Fig. 3). Together, current data suggest that astrocytes may
play a double-edged role in synaptic reorganization post
TBI, releasing enzymes and proteins that have been
observed to both promote and impair synaptic recovery.
Future perspectives
Synapse diversity and selective
synapse vulnerability
The importance of synapse diversity has not been considered
in the context of TBI and is likely to be a crucial factor in
understanding why particular synapses are damaged and
others are resilient. Studies of the protein composition of in-
dividual synapses reveal that synapses are much more di-
verse than previously anticipated; each brain region has a
particular signature of synapse composition, and the synapse
proteomes of brain regions differ from one another
(Micheva et al., 2010; O’Rourke et al., 2012; Broadhead
et al., 2016; Grant, 2018, 2019; Zhu et al., 2018; Cizeron
et al., 2020). These differences encompass many proteins
involved in disease processes, including neurodegeneration,
excitotoxicity and inflammation (Roy et al., 2018a, b). It is
now possible to map the spatial distribution of molecular
and morphological properties of individual synapses across
the mouse brain and generate unbiased catalogues of syn-
apse type, termed the ‘synaptome’ (the diversity of synapses
in the brain or part thereof) (Zhu et al., 2018; Cizeron et al.,
2020). Thus far, these brain-wide methods have been
applied to excitatory postsynaptic markers (PSD95,
SAP102). With a broader range of markers, including those
in inhibitory and monoaminergic synapses and presynaptic
terminals, these synaptomic approaches, combined with
knowledge of the specific proteins and pathways involved
with TBI, are likely to prove crucial in understanding TBI
synaptopathy, providing powerful spatiotemporal insight
into the vulnerable synapse types and brain regions. Synapse
diversity and its spatial organization in the hippocampus
have been shown to store behavioural representations, and
alterations in the spatial organization in a mouse genetic
model of schizophrenia produced altered representations
(Zhu et al., 2018). This suggests that TBI-induced changes
in synapse diversity could underlie cognitive impairments.
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Synaptome mapping of the damaged synapses in TBI could
also be used in conjunction with connectomic data to iden-
tify the affected circuits.
Synaptome mapping has been recently been applied at a
brain-wide scale across the lifespan of the mouse revealing
striking age-dependent differences in synapse composition
(Cizeron et al., 2020). The authors proposed that the differ-
ent numbers of synapse types and subtypes at different ages
would influence vulnerability to damage from inflammation,
toxic proteins and brain injury. This further emphasizes the
importance of understanding synapse diversity and selective
vulnerability in TBI.
Synapses are also known to be dynamic at the level of
protein composition and spine structure. In vivo imaging of
dendritic spines in rodent brain shows that they are not sta-
ble structures, with a high percentage appearing to retract
and rebuild each week (Lendvai et al., 2000; Trachtenberg
et al., 2002; Holtmaat et al., 2005). Furthermore, turnover
studies indicate that the average half-life of the synapse
proteome is a few days to weeks (Ehlers, 2003; Fornasiero
et al., 2018; Heo et al., 2018), while synapse turnover rate
appears to increase with ageing and in Alzheimer’s disease
(Grillo et al., 2013; Liebscher et al., 2014). The ongoing
restructuring of synapses raises the possibility that TBI could
interfere with this process, perhaps preventing the produc-
tion of certain types of synapses, and resulting in a net re-
duction in synapses. In vivo imaging of dendritic spines after
TBI could be used to address the impact of TBI on the phys-
ical turnover of spines, and proteomic methods such as sta-
ble isotope labelling by amino acids in cell culture (SILAC)
(Fornasiero et al., 2018; Heo et al., 2018) could be used to
identify the synapse proteins affected. Ideally, simultaneous
long-term imaging of pre- and postsynaptic terminals in vivo
could reveal the temporal changes in synaptic architecture
and their relationship to axonal and dendritic damage
following TBI.
Clinical monitoring of synapse
damage using PET and fluid
biomarkers
A range of experimental models have been used to examine
the synapse following TBI. Of these, well-established rodent
models such as the CCI and fluid percussion models are
among the most used (Table 1). These models have strengths
including their ability to replicate pathological sequelae
(neuronal/axonal injury and inflammatory response) of TBI
coupled to delivering a consistent and highly reproducible
injury severity (Xiong et al., 2013). However, they also have
a number of important weaknesses such as the need for a
craniotomy and the use of rodents whose lissencephalic
brain structure limits their ability to duplicate the biomech-
anics of the human disease. Studies of human synapses in
TBI have almost exclusively been restricted to post-mortem
brain tissue, and there is a pressing need for methods ena-
bling monitoring of synapse damage in living patients. The
development of radiotracers that bind to the presynaptic
protein synaptic vesicle glycoprotein 2A (SV2A) have shown
promise as tools in PET imaging (Warnock et al., 2014;
Estrada et al., 2016; Nabulsi et al., 2016). The 11C-UCB-J
ligand was found to be safe in first-in-human studies
and had sufficient sensitivity to identify synapse loss in
three patients with mesial temporal sclerosis (Finnema et al.,
2016).
Molecular imaging, although highly useful, requires a
great deal of infrastructure and organization to implement,
limiting its value as a diagnostic tool and for monitoring dis-
ease progression. Biomarkers from fluid samples that can be
collected at the bedside would be very useful and pragmatic
tools for use in the clinic. In recent years, there has been a
growing body of research examining fluid biomarkers and
looking at synaptic proteins in Alzheimer’s disease (Thorsell
et al., 2010; Brinkmalm et al., 2014; Öhrfelt et al., 2016;
Galasko et al., 2019; Lleó et al., 2019). The CSF levels of a
number of candidate proteins are significantly altered in
patients with Alzheimer’s disease compared with control,
including neurogranin, synaptosomal-associated protein 25
(SNAP-25), neuronal pentraxin 2 (NPTX2) and synaptotag-
min (Thorsell et al., 2010; Brinkmalm et al., 2014; Öhrfelt
et al., 2016; Galasko et al., 2019). Discovery proteomic
approaches could be used to identify candidate synaptic pro-
teins in TBI patients before taking these forward to clinical
validation (Carlyle et al., 2018). CSF is not routinely
acquired as part of the TBI clinical management and obtain-
ing a sample typically involves a lumbar puncture, which is
invasive and carries risk. Blood biomarkers would be less in-
vasive and easier to obtain. However, owing to the lower
concentrations of neural proteins compared with CSF, blood
sampling presents a challenge in identifying sensitive
biomarkers.
Synapse therapeutics
In Alzheimer’s disease, synapse loss correlates with early
cognitive decline, making this pathological process an area
of interest to target therapeutically (Scheff et al., 2006;
Jackson et al., 2019). Although the relationship between
synapse loss and cognitive impairment is less clear in TBI,
there is some preclinical data suggesting that reduction in
PSD95 is correlated with behavioural deficits in a murine
TBI model (Wakade et al., 2010). In models of Alzheimer’s
disease, administration of neurotrophic factors such as cil-
iary neurotrophic factor (CNTF) and brain-derived neuro-
trophic factor (BDNF) has been found to rescue synapse loss
and ameliorate cognitive decline (Nagahara et al., 2009;
Kazim et al., 2014). An alternative approach is to target
pathological processes that may drive synaptopathy. As
detailed in this review, inflammation appears to play an im-
portant role in traumatic synaptopathy. Studies in other
pathological processes including Alzheimer’s disease and
schizophrenia have shown that amelioration of inflamma-
tion can reduce synapse loss (Hong et al., 2016; Sellgren
et al., 2019). As the field of synapse therapeutics develops, a
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more nuanced approach that targets specific synapse types
may be required. A study of Fragile X syndrome found that
fenobam, an mGluR5 antagonist, impacted distinct synapse
types, demonstrating that this therapeutic approach is feas-
ible (Wang et al., 2014). However, before synapse type-spe-
cific therapies are developed, the functional role of the
various types needs to be better understood, as well as their
role(s) in neurological disease.
Conclusions
There have been important advances in our understanding
of the role of the synapse in a range of brain disorders. The
synapse appears to play an important role in TBI patho-
physiology and is directly impacted by traumatic insult. TBI
triggers multiple molecular and cellular mechanisms that
interfere with synapse maintenance and potentially synapse
production. To date, the approaches characterizing the tem-
poral and spatial impact of TBI on the synapse have been
limited, both in the scope of brain regions and the number
of synaptic proteins examined. There is a need to utilize
more systematic approaches that quantify large numbers of
synapses across the whole brain, such as synaptome map-
ping (Zhu et al., 2018). Coupled to this, the use of molecu-
lar imaging techniques is vital to translate preclinical
findings of synaptic pathology after TBI into humans
(Finnema et al., 2016). A better characterization of traumat-
ic synaptopathy, coupled to insights into the mechanisms
that underpin it, is vital for the translation of effective
therapies.
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